Monocyte Chemotactic Protein-1 as a Potential Biomarker for Early Anti-Thrombotic Therapy after Ischemic Stroke

International Journal of Molecular Sciences

Hans Worthmann¹  Reinhard Dengler¹  Helmut Schumacher³  Andreas Schwartz²  Wolfgang G. Eisert¹  Ralf Lichtinghagen⁴ 

[1] Department of Neurology, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany; E-Mails:;Department of Neurology, Nordstadt Klinikum Hannover, Haltenhoffstr. 41, Hannover 30167, Germany; E-Mail:;Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Str. 173, Ingelheim 55216, Germany; E-Mail:;Department of Clinical Chemistry, Hannover Medical School, Carl-Neuberg-Str. 1, Hannover 30625, Germany; E-Mail:

关键词: ischemic stroke;    monocyte chemoattractant protein-1 (MCP-1);    antithrombotic therapy;    neuroprotection;    dipyridamole;    acetylsalicylic acid (ASA);   

DOI  :  10.3390/ijms13078670

来源: mdpi

【 摘 要 】

Inflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression. We hypothesized that early treatment with ASA + ER-DP will reduce levels of MCP-1 also in patients with ischemic stroke. The EARLY trial randomized patients with ischemic stroke or TIA to either ASA + ER-DP treatment or ASA monotherapy within 24 h following the event. After 7 days, all patients were treated for up to 90 days with ASA + ER-DP. MCP-1 was determined from blood samples taken from 425 patients on admission and day 8. The change in MCP-1 from admission to day 8 did not differ between patients treated with ASA + ER-DP and ASA monotherapy (p > 0.05). Comparisons within MCP-1 baseline quartiles indicated that patients in the highest quartile (>217–973 pg/mL) showed improved outcome at 90 days if treated with ASA + ER-DP in comparison to treatment with ASA alone (p = 0.004). Our data does not provide any evidence that treatment with ASA + ER-DP lowers MCP-1 in acute stroke patients. However, MCP-1 may be a useful biomarker for deciding on early stroke therapy, as patients with high MCP-1 at baseline appear to benefit from early treatment with ASA + ER-DP.

【 授权许可】

CC BY   
© 2012 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland.